Suchen
Verrica Pharmaceuticals Inc
VRCAZur Watchlist hinzufügen
6.135USD
+0.195+3.28%
Handelsschluss 07/02, 13:00（ET）Kurse um 15 Minuten verzögert
105.39MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Verrica Pharmaceuticals Inc Unternehmen
Verrica Pharmaceuticals Inc. is a dermatology therapeutics company developing and selling medications for skin diseases requiring medical intervention. The Company's product portfolio consists of one approved product with several potential follow-on indications, as well as an additional pipeline product. Its commercial product, YCANTH (VP-102), is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin. YCANTH (VP-102) is being developed for the treatment of molluscum contagiosum in adult and pediatric patients two years of age and older. It is also engaged in developing YCANTH (VP-102) for a potential follow-on indication for the treatment of common warts. Its second development candidate, VP-315, is an oncolytic peptide-based injectable therapy for the potential treatment of dermatology oncologic conditions, including basal cell carcinoma (BCC).
Verrica Pharmaceuticals Inc Informationen
BörsenkürzelVRCA
Name des UnternehmensVerrica Pharmaceuticals Inc
IPO-datumJun 15, 2018
CEORieger (Jayson)
Anzahl der mitarbeiter71
WertpapierartOrdinary Share
GeschäftsjahresendeJun 15
Addresse44 West Gay Street
StadtWEST CHESTER
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl19380
Telefon14844533300
Websitehttps://verrica.com/
BörsenkürzelVRCA
IPO-datumJun 15, 2018
CEORieger (Jayson)
Führungskräfte von Verrica Pharmaceuticals Inc
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Jayson Rieger
Dr. Jayson Rieger
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
183.29K
-0.00%
Mr. David Zawitz
Mr. David Zawitz
Chief Operating Officer
Chief Operating Officer
21.00K
+47.62%
Dr. Noah L. Rosenberg, M.D.
Dr. Noah L. Rosenberg, M.D.
Chief Medical Officer
Chief Medical Officer
2.36K
--
Dr. Diem Nguyen, Ph.D.
Dr. Diem Nguyen, Ph.D.
Independent Director
Independent Director
10.00
--
Dr. Gavin Corcoran
Dr. Gavin Corcoran
Independent Director
Independent Director
2.00
--
Mr. Paul B. Manning
Mr. Paul B. Manning
Chairman of the Board
Chairman of the Board
--
--
Mr. Mark A. Prygocki, Sr.
Mr. Mark A. Prygocki, Sr.
Independent Director
Independent Director
--
--
Dr. Lawrence Eichenfield, M.D.
Dr. Lawrence Eichenfield, M.D.
Independent Director
Independent Director
--
--
Mr. John J. Kirby
Mr. John J. Kirby
Interim Chief Financial Officer, Interim Principal Financial Officer
Interim Chief Financial Officer, Interim Principal Financial Officer
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Jayson Rieger
Dr. Jayson Rieger
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
183.29K
-0.00%
Mr. David Zawitz
Mr. David Zawitz
Chief Operating Officer
Chief Operating Officer
21.00K
+47.62%
Dr. Noah L. Rosenberg, M.D.
Dr. Noah L. Rosenberg, M.D.
Chief Medical Officer
Chief Medical Officer
2.36K
--
Dr. Diem Nguyen, Ph.D.
Dr. Diem Nguyen, Ph.D.
Independent Director
Independent Director
10.00
--
Dr. Gavin Corcoran
Dr. Gavin Corcoran
Independent Director
Independent Director
2.00
--
Mr. Paul B. Manning
Mr. Paul B. Manning
Chairman of the Board
Chairman of the Board
--
--
Häufig gestellte Fragen
Wer sind die fünf größten Anteilseigner von Verrica Pharmaceuticals Inc?
Die fünf größten Anteilseigner von Verrica Pharmaceuticals Inc sind: Dr. Jayson Rieger
Wie viele Institutionen halten Anteile an Verrica Pharmaceuticals Inc (VRCA)?
Mit Stand vom 2026Q1 halten 180 Institutionen Anteile an Verrica Pharmaceuticals Inc, mit einem Gesamtmarktwert von etwa 5.43M, was 31.63% der Gesamtanteile entspricht. Im Vergleich zum 2025Q4 ist der institutionelle Aktienbesitz um 1273710.00 gestiegen.